In this study, we screened our in-house library of small molecule compounds and identified that Abemaciclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor approved by FDA for breast cancer treatment [16], as the strongest inhibitor of YAP1 activity. Here, CDK4 is linked to breast carcinoma.